References
Key articles
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision. Geneva: WHO; 2022.Full text
Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528.Full text Abstract
Faraone SV, Banaschewski T, Coghill D, et al. The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.Full text Abstract
Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020 Feb/Mar;41 Suppl 2S:S35-S57.Full text Abstract
Reference articles
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision. Geneva: WHO; 2022.Full text
3. Schonwald A, Lechner E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr. 2006 Apr;18(2):189-95. Abstract
4. Barkley RA. Attention deficit hyperactivity disorder: a clinical handbook, 3rd ed. New York: Guilford; 2005.
5. Faraone SV, Biederman J, Jetton JG, et al. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol Med. 1997 Mar;27(2):291-300. Abstract
6. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):21-9. Abstract
7. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):37-44. Abstract
8. Faraone SV, Biederman J. Do attention deficit hyperactivity disorder and major depression share familial risk factors? J Nerv Ment Dis. 1997 Sep;185(9):533-41. Abstract
9. Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):997-1008. Abstract
10. Spencer TJ, Biederman MD, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007 Aug;32(8):631-42. Abstract
11. Pliszka SR, Carlson CL, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York, NY: Guilford; 1999.
12. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942-8.Full text Abstract
13. Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015 Mar;56(3):345-65. Abstract
14. Centers for Disease Control and Prevention. Data and statistics about ADHD. Oct 2023 [internet publication].Full text
15. Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014 Apr;43(2):434-42.Full text Abstract
16. Collishaw S. Annual research review: Secular trends in child and adolescent mental health. J Child Psychol Psychiatry. 2015 Mar;56(3):370-93. Abstract
17. Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am. 2004 Jun;27(2):225-32. Abstract
18. Sayal K, Prasad V, Daley D, et al. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018 Feb;5(2):175-86. Abstract
19. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the National Health Interview Survey. J Atten Disord. 2005 Nov;9(2):392-401. Abstract
20. Epstein JN, Willoughby M, Valencia EY, et al. The role of children's ethnicity in the relationship between teacher ratings of attention-deficit/hyperactivity disorder and observed classroom behavior. J Consult Clin Psychol. 2005 Jun;73(3):424-34. Abstract
21. Cénat JM, Blais-Rochette C, Morse C, et al. Prevalence and risk factors associated with attention-deficit/hyperactivity disorder among US black individuals: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Jan 1;78(1):21-8.Full text Abstract
22. Langley K, Holmans PA, van den Bree MB, et al. Effects of low birth weight, maternal smoking in pregnancy and social class on the phenotypic manifestation of attention deficit hyperactivity disorder and associated antisocial behavior: investigation in a clinical sample. BMC Psychiatry. 2007 Jun 20;7:26.Full text Abstract
23. DuPaul GJ, Gormley MJ, Laracy SD. Comorbidity of LD and ADHD: implications of DSM-5 for assessment and treatment. J Learn Disabil. 2013 Jan-Feb;46(1):43-51. Abstract
24. Dunn DW, Bourgeois BFD. Learning disabilities and ADHD in children with epilepsy. In: Duchowny M, Cross JH, Arzimanoglou A, eds. Pediatric epilepsy. New York, NY: McGraw Hill Medical; 2013:323-9.
25. Yao S, Kuja-Halkola R, Martin J, et al. Associations between attention-deficit/hyperactivity disorder and various eating disorders: a Swedish nationwide population study using multiple genetically informative approaches. Biol Psychiatry. 2019 Oct 15;86(8):577-86.Full text Abstract
26. Groenman AP, Janssen TWP, Oosterlaan J. Childhood psychiatric disorders as risk factor for subsequent substance abuse: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):556-69. Abstract
27. Fuller-Thomson E, Lewis DA, Agbeyaka S. Attention-deficit/hyperactivity disorder and alcohol and other substance use disorders in young adulthood: findings from a Canadian nationally representative survey. Alcohol Alcohol. 2022 May 10;57(3):385-95.Full text Abstract
28. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003 Jan;111(1):179-85. Abstract
29. Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry. 2011 Jul;24(4):280-5. Abstract
30. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1313-23. Abstract
31. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev. 2006 Aug;26(4):396-432. Abstract
32. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. Abstract
33. Thapar A. Discoveries on the genetics of ADHD in the 21st century: new findings and their implications. Am J Psychiatry. 2018 Oct 1;175(10):943-50.Full text Abstract
34. Martin J, O'Donovan MC, Thapar A, et al. The relative contribution of common and rare genetic variants to ADHD. Transl Psychiatry. 2015 Feb 10;5(2):e506.Full text Abstract
35. Nigg J, Nikolas M, Burt SA. Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):863-73. Abstract
36. Walton E, Pingault JB, Cecil CA, et al. Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study. Mol Psychiatry. 2017 Feb;22(2):250-6. Abstract
37. Thapar A, O'Donovan MC, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet. 2005 Oct 15;14 Spec No 2:R275-82.Full text Abstract
38. Groen-Blokhuis MM, Middeldorp CM, van Beijsterveldt CE, et al. Evidence for a causal association of low birth weight and attention problems. J Am Acad Child Adolesc Psychiatry. 2011 Dec;50(12):1247-54. Abstract
39. Sourander A, Sucksdorff M, Chudal R, et al. Prenatal cotinine levels and ADHD among offspring. Pediatrics. 2019 Mar;143(3):e20183144.Full text Abstract
40. Class QA, Rickert ME, Larsson H, et al. Fetal growth and psychiatric and socioeconomic problems: population-based sibling comparison. Br J Psychiatry. 2014 Nov;205(5):355-61.Full text Abstract
41. Lahat E, Heyman E, Livne A, et al. Iron deficiency in children with attention deficit hyperactivity disorder. Isr Med Assoc J. 2011 Sep;13(9):530-3. Abstract
42. Froehlich TE, Anixt JS, Loe IM, et al. Update on environmental risk factors for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2011 Sep;13(9):333-44. Abstract
43. Rodriguez A, Bohlin G. Are maternal smoking and stress during pregnancy related to ADHD symptoms in children? J Child Psychol Psychiatry. 2005 Mar;26(3):246-54. Abstract
44. Nilsen FM, Tulve NS. A systematic review and meta-analysis examining the interrelationships between chemical and non-chemical stressors and inherent characteristics in children with ADHD. Environ Res. 2020 Jan;180:108884. Abstract
45. Björkenstam E, Björkenstam C, Jablonska B, et al. Cumulative exposure to childhood adversity, and treated attention deficit/hyperactivity disorder: a cohort study of 543 650 adolescents and young adults in Sweden. Psychol Med. 2018 Feb;48(3):498-507. Abstract
46. Knopik VS, Sparrow EP, Madden PA, et al. Contributions of parental alcoholism, prenatal substance exposure, and genetic transmission to child ADHD risk: a female twin study. Psychol Med. 2005 May;35(5):625-35. Abstract
47. Kennedy M, Kreppner J, Knights N, et al. Early severe institutional deprivation is associated with a persistent variant of adult attention-deficit/hyperactivity disorder: clinical presentation, developmental continuities and life circumstances in the English and Romanian Adoptees study. J Child Psychol Psychiatry. 2016 Oct;57(10):1113-25.Full text Abstract
48. Kreppner JM, O'Connor TG, Rutter M. Can inattention/overactivity be an institutional deprivation syndrome? J Abnorm Child Psychol. 2001 Dec;29(6):513-28. Abstract
49. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020 Feb 8;395(10222):450-62. Abstract
50. Greenhill LL. Stimulant medication treatment of children with attention deficit hyperactivity disorder. In: Jensen PS, Cooper JR, eds. Attention deficit hyperactivity disorder: state of science. best practices. Kingston, NH: Civic Research Institute 2002:9-1-9-27.
51. Wilens TE. Mechanism of action of agents used in attention deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67 Suppl 8:32-8. Abstract
52. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Abstract
53. Sengupta SM, Grizenko N, Thakur GA, et al. Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. J Psychiatry Neurosci. 2012 Feb;37(2):129-37.Full text Abstract
54. Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011 Dec 4;44(4):78-84. Abstract
55. Wargelius HL, Malmberg K, Larsson JO, et al. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr Genet. 2012 Feb;22(1):42-5. Abstract
56. Cortese S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012 Sep;16(5):422-33. Abstract
57. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005 Jun 1;57(11):1336-46. Abstract
58. Castellanos FX, Sonuga-Barke EJ, Milham MP, et al. Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci. 2006 Mar;10(3):117-23. Abstract
59. Strauß M, Ulke C, Paucke M, et al. Brain arousal regulation in adults with attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res. 2018 Mar;261:102-8. Abstract
60. Metin B, Roeyers H, Wiersema JR, et al. A meta-analytic study of event rate effects on Go/No-Go performance in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012 Dec 15;72(12):990-6. Abstract
61. Valera EM, Faraone SV, Murray KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007 Jun 15;61(12):1361-9. Abstract
62. Duerden EG, Tannock R, Dockstader C. Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. Brain Res. 2012 Mar 22;1445:82-91. Abstract
63. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry. 2017 Apr;4(4):310-9.Full text Abstract
64. Nakao T, Radua J, Rubia K, et al. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry. 2011 Nov;168(11):1154-63. Abstract
65. Lukito S, Norman L, Carlisi C, et al. Comparative meta-analyses of brain structural and functional abnormalities during cognitive control in attention-deficit/hyperactivity disorder and autism spectrum disorder. Psychol Med. 2020 Apr;50(6):894-919. Abstract
66. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005 Jun 1;57(11):1273-84. Abstract
67. Mills KL, Bathula D, Dias TG, et al. Altered cortico-striatal-thalamic connectivity in relation to spatial working memory capacity in children with ADHD. Front Psychiatry. 2012 Jan 25;3:2.Full text Abstract
68. Gallo EF, Posner J. Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms. Lancet Psychiatry. 2016 Jun;3(6):555-67. Abstract
69. Posner J, Park C, Wang Z. Connecting the dots: a review of resting connectivity MRI studies in attention-deficit/hyperactivity disorder. Neuropsychol Rev. 2014 Mar;24(1):3-15. Abstract
70. Tomasi D, Volkow ND. Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012 Mar 1;71(5):443-50. Abstract
71. Cortese S, Castellanos FX. Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep. 2012 Oct;14(5):568-78. Abstract
72. Chen L, Hu X, Ouyang L, et al. A systematic review and meta-analysis of tract-based spatial statistics studies regarding attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2016 Sep;68:838-47. Abstract
73. Szatmari P, Saigal S, Rosenbaum P, et al. Psychiatric disorders at five years among children with birth weights less than 1000g: a regional perspective. Dev Med Child Neurol. 1990 Nov;32(11):954-62. Abstract
74. Mick E, Biederman J, Prince J, et al. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002 Feb;23(1):16-22. Abstract
75. Masur D, Shinnar S, Cnaan A, et al; Childhood Absence Epilepsy Study Group. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013 Oct 29;81(18):1572-80.Full text Abstract
76. Avella-Garcia CB, Julvez J, Fortuny J, et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. Int J Epidemiol. 2016 Dec 1;45(6):1987-96.Full text Abstract
77. Brandlistuen RE, Ystrom E, Nulman I, et al. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol. 2013 Dec;42(6):1702-13.Full text Abstract
78. Ji Y, Azuine RE, Zhang Y, et al. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry. 2020 Feb 1;77(2):180-9.Full text Abstract
79. Rutter M, Cox A, Tupling C, et al. Attainment and adjustment in two geographical areas. 1 - The prevalence of psychiatric disorders. Br J Psychiatry. 1975 Jun;126:493-509. Abstract
80. Biederman J, Milberger S, Faraone SV, et al. Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry. 1995 Jun;52(6):464-70. Abstract
81. Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter's index of adversity in a sample of boys and girls with and without ADHD. Am J Psychiatry. 2002 Sep;159(9):1556-62.Full text Abstract
82. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006 Dec;114(12):1904-9.Full text Abstract
83. Max JE, Arndt S, Castillo CS, et al. Attention-deficit hyperactivity disorder symptomatology after traumatic brain injury: a prospective study. J Am Acad Child Adolesc Psychiatry. 1998 Aug;37(8):841-7. Abstract
84. Adeyemo BO, Biederman J, Zafonte R, et al. Mild traumatic brain injury and ADHD: a systematic review of the literature and meta-analysis. J Atten Disord. 2014 Oct;18(7):576-84. Abstract
85. Cortese S, Angriman M, Lecendreux M, et al. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother. 2012 Oct;12(10):1227-40. Abstract
86. Tseng PT, Cheng YS, Yen CF, et al. Peripheral iron levels in children with attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Sci Rep. 2018 Jan 15;8(1):788.Full text Abstract
87. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):991-1000. Abstract
88. Chang JP, Su KP, Mondelli V, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology. 2018 Feb;43(3):534-45.Full text Abstract
89. Gillies D, Leach MJ, Perez Algorta G. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD007986. Abstract
90. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528.Full text Abstract
91. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. Sep 2019 [internet publication].Full text
92. Faraone SV, Banaschewski T, Coghill D, et al. The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.Full text Abstract
93. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1015-37. Abstract
94. Chang LY, Wang MY, Tsai PS. Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis. Pediatrics. 2016 Mar;137(3):e20152749. Abstract
95. Pineda DA, Puerta IC, Aguirre DC, et al. The role of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. Pediatr Neurol. 2007 Jun;36(6):373-81. Abstract
96. Weiler MD, Bernstein JH, Bellinger DC, et al. Processing speed in children with attention deficit/hyperactivity disorder, inattentive type. Child Neuropsychol. 2000 Sep;6(3):218-34. Abstract
97. American Academy of Pediatrics Council on Environmental Health. Five things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. May 2021 [internet publication].Full text
98. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder. Circulation. 2008 May 6;117(18):2407-23.Full text Abstract
99. de Boo GM, Prins PJ. Social incompetence in children with ADHD: possible moderators and mediators in social-skills training. Clin Psychol Rev. 2007 Jan;27(1):78-97. Abstract
100. Steiner H, Remsing L; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):126-41.Full text Abstract
101. Richardson LP, McCauley E, Grossman DC, et al. Evaluation of the patient health questionnaire-9 item for detecting major depression among adolescents. Pediatrics. 2010 Dec;126(6):1117-23. Abstract
102. Woolf AD, Goldman R, Bellinger DC. Update on the clinical management of childhood lead poisoning. Pediatr Clin North Am. 2007 Apr;54(2):271-94. Abstract
103. Sandoval C, Jayabose S, Eden AN. Trends in diagnosis and management of iron deficiency during infancy and early childhood. Hematol Oncol Clin North Am. 2004 Dec;18(6):1423-38. Abstract
104. Streissguth AP, O'Malley K. Neuropsychiatric implications and long-term consequences of fetal alcohol spectrum disorders. Semin Clin Neuropsychiatry. 2000 Jul;5(3):177-90. Abstract
105. Wattendorf DJ, Muenke M. Fetal alcohol spectrum disorders. Am Fam Physician. 2005 Jul 15;72(2):279-82;285. Abstract
106. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989 Apr;160(4):863-8. Abstract
107. Kaufman DM. Congenital cerebral impairments. In: Kaufman DM. Clinical neurology for psychiatrists. 6th ed. Bronx, NY: Elsevier; 2007:295-311.
108. McKeown NJ, Tews MC, Gossain VV, et al. Hyperthyroidism. Emerg Med Clin North Am. 2005 Aug;23(3):669-85, viii. Abstract
109. Meltzer LJ. Mindell JA. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am. 2006 Dec;29(4):1059-76. Abstract
110. Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020 Feb/Mar;41 Suppl 2S:S35-S57.Full text Abstract
111. Levy SJ, Williams JF, Committee On Substance Use And Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016 Jul;138(1):e20161211.Full text Abstract
112. Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines (4.1th ed). 2020 [internet publication].Full text
113. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999 Dec:56(12):1073-86.Full text Abstract
114. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit hyperactivity disorder. Pediatrics. 2004 Apr;113(4):754-61. Abstract
115. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):989-1002. Abstract
116. Vaughan B, Kratochvil CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55. Abstract
117. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-38.Full text Abstract
118. National Institute for Health and Care Excellence. Clinical knowledge summaries. Scenario: management of attention deficit hyperactivity disorder (ADHD). Jan 2021 [internet publication].Full text
119. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284-1293. Abstract
120. Jones K, Daley D, Hutchings J, et al. Efficacy of the Incredible Years Programme as an early intervention for children with conduct problems and ADHD: long-term follow-up. Child Care Health Dev. 2008 May;34(3):380-90. Abstract
121. Greenhill LL, Posner K, Vaughan BS, et al. Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):347-66, ix. Abstract
122. Harstad E, Shults J, Barbaresi W, et al. α2-adrenergic agonists or stimulants for preschool-age children with attention-deficit/hyperactivity disorder. JAMA. 2021 May 25;325(20):2067-75. Abstract
123. Santosh P. Stimulant medication to treat attention-deficit/hyperactivity disorder. BMJ. 2017 Jul 14;358:j2945. Abstract
124. Storebø OJ, Storm MRO, Pereira Ribeiro J, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. Abstract
125. Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016 Feb 4;(2):CD009996.Full text Abstract
126. Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018 May 9;(5):CD012069.Full text Abstract
127. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353-364. Abstract
128. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007 Aug;28(4):265-73. Abstract
129. Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-32.Full text Abstract
130. Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis. JAMA Pediatr. 2019 Jul 1;173(7):630-39.Full text Abstract
131. Greenhill LL, Swanson JM, Hechtman L, et al. Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2020 Aug;59(8):978-89. Abstract
132. Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019 Mar 21;380(12):1128-38.Full text Abstract
133. Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry. 2019 Aug;6(8):651-8.Full text Abstract
134. Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014 Aug;55(8):878-85. Abstract
135. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Jun 2023 [internet publication].Full text
136. Man KKC, Häge A, Banaschewski T, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry. 2023 May;10(5):323-33. Abstract
137. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011 Nov 17;365(20):1896-904. Abstract
138. Liang EF, Lim SZ, Tam WW, et al. The Effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): systematic review, meta-analysis, and meta-regression. Int J Environ Res Public Health. 2018 Aug 20;15(8):1789.Full text Abstract
139. Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psychiatry. 2019 Oct;28(10):1283-93. Abstract
140. Shin JY, Roughead EE, Park BJ, et al. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016 May 31;353:i2550.Full text Abstract
141. Brams M, Moon E, Pucci M, et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010 Aug;26(8):1809-25. Abstract
142. Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan;12(4):308-15. Abstract
143. Arnold LE. Methylphenidate vs. amphetamine: a comparative review. J Atten Disord. 2000 Jan;3(4):200-11.
144. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Abstract
145. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;(6):CD007990.Full text Abstract
146. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84. Abstract
147. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001 Nov;108(5):E83. Abstract
148. Buitelaar J, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007 Mar;61(1):694-9. Abstract
149. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. Abstract
150. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007 Mar;41(3):222-30. Abstract
151. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008 Jun;165(6):721-30.Full text Abstract
152. Scott NG, Ripperger-Suhler J, Rajab MH, et al. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2010 Jun;20(3):197-203. Abstract
153. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007 Sep;46(9):1119-27. Abstract
154. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Atomoxetine. Jul 2017 [internet publication].Full text
155. Liu Q, Zhang H, Fang Q, et al. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. J Clin Exp Neuropsychol. 2017 Nov;39(9):854-65. Abstract
156. Banaschewski T, Roessner V, Dittman RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):I102-16. Abstract
157. Rains A, Scahill L, Hamrin V. Nonstimulant medications for the treatment of ADHD. J Child Adolesc Psychiatr Nurs. 2006 Feb;19(1):44-7. Abstract
158. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008 Jan;121(1):e73-84. Abstract
159. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85. Abstract
160. Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65. Abstract
161. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010 Sep;24(9):755-68. Abstract
162. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011 Jun;127(6):e1406-13. Abstract
163. Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr Drugs. 2011 Oct 1;13(5):329-36. Abstract
164. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10);1314-21. Abstract
165. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005 Apr 1;57(7):793-801. Abstract
166. Langberg JM, Arnold LE, Flowers AM, et al. Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol. 2010;39(2):220-33. Abstract
167. Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016 May 10;315(18):1997-2008. Abstract
168. Storebø OJ, Elmose Andersen M, Skoog M, et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2019 Jun 21;(6):CD008223.Full text Abstract
169. Asarnow JR, Rozenman M, Wiblin J, et al. Integrated medical-behavioral care compared with usual primary care for child and adolescent behavioral health: a meta-analysis. JAMA Pediatr. 2015 Oct;169(10):929-37.Full text Abstract
170. Coughlin CG, Cohen SC, Mulqueen JM, et al. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015 Oct;25(8):611-7. Abstract
171. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):147-58. Abstract
172. Harstad E, Levy S, Committee on Substance Abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014 Jul;134(1):e293-301.Full text Abstract
173. Clinical Guideline Committee (CGC) Members; ASAM Team; AAAP Team; IRETA Team. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun 01;18(1):1-56.Full text
174. Barkla XM, McArdle PA, Newbury-Birch D. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? a systematic review of the literature. BMC Psychiatry. 2015 Oct 30;15:270.Full text Abstract
175. Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Sep;54(9):728-36. Abstract
176. Chen Q, Sjölander A, Runeson B, et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014 Jun 18;348:g3769.Full text Abstract
177. Huang KL, Wei HT, Hsu JW, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry. 2018 Apr;212(4):234-8.Full text Abstract
178. Liang SH, Yang YH, Kuo TY, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Res Dev Disabil. 2018 Jan;72:96-105.Full text Abstract
179. Man KK, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry. 2017 Oct 1;74(10):1048-55. Abstract
180. Valdes AM, Walter J, Segal E, et al. Role of the gut microbiota in nutrition and health. BMJ. 2018 Jun 13;361:k2179.Full text Abstract
181. Cagigal C, Silva T, Jesus M, et al. Does diet affect the symptoms of ADHD? Curr Pharm Biotechnol. 2019;20(2):130-6. Abstract
182. Pelsser LM, Frankena K, Toorman J, et al. Diet and ADHD, reviewing the evidence: a systematic review of meta-analyses of double-blind placebo-controlled trials evaluating the efficacy of diet interventions on the behavior of children with ADHD. PLoS One. 2017;12(1):e0169277.Full text Abstract
183. Johnstone JM, Hatsu I, Tost G, et al. Micronutrients for attention-deficit/hyperactivity disorder in youths: a placebo-controlled randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2022 May;61(5):647-61.Full text Abstract
184. Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev. 2014 Aug;34(6):496-505. Abstract
185. Nigg JT, Lewis K, Edinger T, et al. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):86-97.e8. Abstract
186. Robinette LM, Hatsu IE, Johnstone JM, et al. Fruit and vegetable intake is inversely associated with severity of inattention in a pediatric population with ADHD symptoms: the MADDY Study. Nutr Neurosci. 2023 Jun;26(6):572-81.Full text Abstract
187. Li L, Taylor MJ, Bälter K, et al. Attention-deficit/hyperactivity disorder symptoms and dietary habits in adulthood: A large population-based twin study in Sweden. Am J Med Genet B Neuropsychiatr Genet. 2020 Dec;183(8):475-85.Full text Abstract
188. Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994 Feb 3;330(5):301-7.Full text Abstract
189. Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children. a meta-analysis. JAMA. 1995 Nov 22-29;274(20):1617-21. Abstract
190. Centers for Disease Control and Prevention. Childhood Nutrition Facts. Aug 2022 [internet publication].Full text
191. Evans S, Ling M, Hill B, et al. Systematic review of meditation-based interventions for children with ADHD. Eur Child Adolesc Psychiatry. 2018 Jan;27(1):9-27. Abstract
192. Karpouzis F, Bonello R, Pollard H. Chiropractic care for paediatric and adolescent attention-deficit/hyperactivity disorder: a systematic review. Chiropr Osteopat. 2010 Jun 2;18:13.Full text Abstract
193. American Academy of Pediatrics. Subcommittee on attention-deficit/hyperactivity disorder and committee on quality improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct;108(4):1033-44. Abstract
194. ClinicalTrials.gov. KP415 classroom study in children (6-12 years of age) with ADHD. NCT03292952. Jun 2020 [internet publication].Full text
195. Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021 Apr;43(4):684-700.Full text Abstract
196. Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020 Aug;42(8):1452-66.Full text Abstract
197. Nasser A, Kosheleff AR, Hull JT, et al. Translating attention-deficit/hyperactivity disorder rating scale-5 and Weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (viloxazine extended-release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021 Apr;31(3):214-26.Full text Abstract
198. McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):403-11.e3.Full text Abstract
199. National Institute for Health and Care Excellence. Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. Jan 2023 [internet publication].Full text
200. Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines. 4th ed. 2020 [internet publication].Full text
201. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990 Jul;29(4):546-57. Abstract
202. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of ADHD and related disorders. Arch Gen Psychiatry. 1996 May;53(5):437-46. Abstract
203. Curry AE, Yerys BE, Metzger KB, et al. Traffic crashes, violations, and suspensions among young drivers with ADHD. Pediatrics. 2019 Jun;143(6):e20182305.Full text Abstract
204. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004 Feb;45(2):195-211. Abstract
205. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adoles Pscyhiatry. 2006 Feb;45(2):192-202. Abstract
206. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004 Feb;14(2):65-73. Abstract
207. Kidwell KM, Van Dyk TR, Lundahl A, et al. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015 Dec;136(6):1144-53. Abstract
208. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005 Aug;90(8):801-6. Abstract
209. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1015-27. Abstract
210. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996 Nov;35(11):1460-9. Abstract
211. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006 Apr 6;354(14):1445-8.Full text Abstract
212. Hammerness PG, Perrin JM, Shelley-Abrahamson R, et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90. Abstract
213. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):614-9. Abstract
214. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention-deficit hyperactivity disorder. Pediatrics. 2002 Aug;110(2 Pt 1):258-66. Abstract
215. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit hyperactivity disorder. Pediatrics. 2001 Oct;108(4):883-92. Abstract
216. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999 Apr;56(4):330-6.Full text Abstract
217. Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. J Dev Behav Pediatr. 1990 Oct;11(5):269-71. Abstract
218. Winhusen TM, Lewis DF, Riggs PD, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011 Oct;21(5):455-63. Abstract
219. Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics. 2014 Jun;133(6):1070-80.Full text Abstract
220. Nigg JT, Johnstone JM, Musser ED, et al. Attention-deficit/hyperactivity disorder (ADHD) and being overweight/obesity: new data and meta-analysis. Clin Psychol Rev. 2016 Feb;43:67-79. Abstract
221. Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry. 2016 Jan;173(1):34-43.Full text Abstract
222. Østergaard SD, Dalsgaard S, Faraone SV, et al. Teenage parenthood and birth rates for individuals with and without attention-deficit/hyperactivity disorder: a nationwide cohort study. J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):578-84.e3. Abstract
223. Hua MH, Huang KL, Hsu JW, et al. Early pregnancy risk among adolescents with ADHD: a nationwide longitudinal study. J Atten Disord. 2021 Jul;25(9):1199-1206. Abstract
224. Skoglund C, Kopp Kallner H, Skalkidou A, et al. Association of attention-deficit/hyperactivity disorder with teenage birth among women and girls in Sweden. JAMA Netw Open. 2019 Oct 2;2(10):e1912463.Full text Abstract
225. Pohlabeln H, Rach S, De Henauw S, et al. Further evidence for the role of pregnancy-induced hypertension and other early life influences in the development of ADHD: results from the IDEFICS study. Eur Child Adolesc Psychiatry. 2017 Aug;26(8):957-67. Abstract
226. Yeh JY, Hou TY, Tseng WT, et al. Association between attention deficit hyperactivity disorder and risk of burn injury: a propensity-matched cohort study. Neuropsychiatr Dis Treat. 2020;16:1249-55.Full text Abstract
227. Nelson LD, Guskiewicz KM, Marshall SW, et al. Multiple self-reported concussions are more prevalent in athletes with ADHD and learning disability. Clin J Sport Med. 2016 Mar;26(2):120-7. Abstract
228. Chang Z, Lichtenstein P, D'Onofrio BM, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014 Mar;71(3):319-25.Full text Abstract
229. Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38(1):113-28. Abstract
Use of this content is subject to our disclaimer